Katy Bortel, RN, MS, CCRP

Central DuPage HospitalWinfield, Illinois - 60190 |
- CLINICAL TRIALS 1
- CONDITIONS1
- INTERVENTIONS2
- SINCE2008

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
September 2008 - October 2014
Ovarian Neoplasms
Morab-003 (Farletuzumab)
0.9% Saline



